ArcticZymes Technologies launches AZscriptT Reverse Transcriptase

18 Dec 2022 20:57 CET

Tromsø, Norway, 16[th] December 2022 - ArcticZymes Technologies ASA (OSE: AZT)
launches AZscriptT Reverse Transcriptase

ArcticZymes Technologies (AZT) today announces the launch of its new product
AZscriptT Reverse Transcriptase (RT).

Launching the AZscript[TM] RT product is a natural expansion of the Company's
molecular tools portfolio. Reverse transcriptases are critical enzymes for
molecular diagnostics and are used to convert RNA into DNA in a broad range of
applications such as the detection of pathogenic RNA virus in diagnostic PCR
workflows or the analysis of transcriptomes in Next Generation Sequencing (NGS).

By expanding the portfolio the Company expects to see synergies with our
existing products supporting RT-qPCR and RT-LAMP workflows in molecular research
and diagnostics.

The global molecular tools market has seen a significant increase in demand in
recent years. Being able to serve customers with a more complete enzyme offering
will be an important driver for continued sales growth in the molecular tools
business.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

"Today our customers are using Reverse Transcriptases from other suppliers
seamlessly alongside AZT´s dsDNases and Cod UNG in their RNA workflows. The
launch of AZscript[TM] Reverse Transcriptase will allow the Company to provide a
reverse transcriptase that is optimised to work in combination with our other
enzymes in customer workflows."

For more information, please contact:

ArcticZymes Technologies
CEO, Jethro Holter Tel: +47 46 85 91 46
CFO, Børge Sørvoll Tel: +47 95 29 01 87
ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]
ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies
in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at
the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.

More information:
Access the news on Oslo Bors NewsWeb site

578501_AZT_AZscript_RT_release_16122022.pdf